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Abstract  
Knock-out mouse models have been extensively used to study the antiviral activity of interferon-induced 
protein with tetratricopeptide repeats (IFIT). Human IFIT1 binds to cap0 (m7GpppN) RNA, which lacks 
methylation on the first and second cap-proximal nucleotides (cap1, m7GpppNm, and cap2, 
m7GpppNmNm, respectively). These modifications are signatures of ‘self’ in higher eukaryotes, while 
unmodified cap0-RNA is recognised as foreign and, therefore, potentially harmful to the host cell. IFIT1 
inhibits translation at the initiation stage by competing with the cap-binding initiation factor complex, 
eIF4F, restricting infection by certain viruses that possess ‘non-self’ cap0-mRNAs. However, in mice and 
other rodents the IFIT1 orthologue has been lost and the closely-related Ifit1b has been duplicated twice, 
yielding three paralogues: Ifit1, Ifit1b and Ifit1c. While murine Ifit1 is similar to human IFIT1 in its cap0-
RNA binding selectivity, the roles of Ifit1b and Ifit1c are unknown. Here, we found that Ifit1b preferentially 
binds to cap1-RNA, while binding is much weaker to cap0- and cap2-RNA. In murine cells, we show that 
Ifit1b can modulate host translation and restrict wildtype mouse coronavirus infection. We found that Ifit1c 
acts as a stimulatory cofactor for both Ifit1 and Ifit1b, promoting their translation inhibition. In this way, 
Ifit1c acts in an analogous fashion to human IFIT3, which is a cofactor to human IFIT1. This work clarifies 
similarities and differences between the human and murine IFIT families, to facilitate better design and 
interpretation of mouse models of human infection, and sheds light on the evolutionary plasticity of the 
IFIT family. 
 
Introduction 
Viruses with capped positive-sense RNA genomes must convincingly mimic host mRNA to avoid 
recognition by cell-intrinsic defence systems. In eukaryotes, the mRNA cap consists of a guanosine 
nucleotide covalently linked to the first RNA nucleotide by a 5ʹ-5ʹ triphosphate bridge (capG, GpppNN), 
which is methylated at the N-7 position (cap0, m7GpppNN) to facilitate nuclear export and translation 
initiation factor recruitment. In higher eukaryotes, including insects and vertebrates, mRNA is further 
modified by methylation on the 2ʹ-hydroxyl of the first and second cap-proximal nucleotide riboses (cap1, 
m7GpppNmN and cap2, m7GpppNmNm) (1). Coronaviruses, including severe acute respiratory syndrome 
(SARS)-CoV and the newly-emerged SARS-CoV-2, and mosquito-borne flaviviruses, including dengue virus 
and Zika virus (ZIKV), encode viral 2ʹ-O-methyltransferases to produce cap1 viral mRNAs (2), which 
effectively mimic those of the host to avoid immune surveillance. 
 
Sensing of mRNA 2′-O-methylation in vertebrates is primarily mediated by a family of antiviral RNA 
binding proteins known as interferon-induced proteins with tetratricopeptide repeats (IFIT). In most 
mammals, including humans, the IFIT family comprises five members: IFIT1, IFIT1B, IFIT2, IFIT3 and 
IFIT5 (3, 4). IFITs are comprised of tandem tetratricopeptide repeat (TPR) motifs which form superhelical 
N- and C-terminal domains joined by a pivot domain of variable length and flexibility (5). Structures of 
human IFIT1 and IFIT5 have shown that the groove between these N- and C-terminal domains is lined with 
positively charged residues which non-specifically coordinate the phosphate backbone of single-stranded 
RNA (6–10). As such IFIT5 binds specifically to single-stranded RNA that lacks a 5′ cap (5′ppp) (7, 11, 
12). IFIT1 has an additional hydrophobic cavity within the N-terminus which can accommodate the 5′ cap, 
and consequently has high affinity for cap0 RNA (8). However, due to steric restrictions within the mRNA 
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binding channel, IFIT1 binds to cap1 RNA with much lower affinity and cannot bind to cap2-RNA (8, 13). 
Binding to the 5′ extremity of cap0 transcripts allows IFIT1 to effectively out-compete the cap-binding 
eukaryotic translation initiation factor (eIF) 4F, thereby inhibiting translation at the initiation stage (11). 
While IFIT3 does not bind RNA directly, its ability to form a complex with IFIT1 via a conserved C-
terminal interaction motif greatly increases IFIT1 stability and cap0-RNA binding affinity, thereby 
promoting IFIT1 antiviral activity (13, 14). 
 
Mouse models have been used extensively to examine the role of IFIT proteins in regulating human disease 
(see (15)). Like human IFIT1, murine Ifit1 can bind to cap0 RNA with high affinity (16). In vivo, mutation 
of the virally-encoded 2′-O-methyltransferase in a number of flavivirus and coronavirus species severely 
attenuated viral replication, and vaccination with these viruses can protect mice from challenge with 
virulent strains (17–22). Virulence was partially or fully restored upon Ifit1 knockout, indicating specific 
antiviral activity against cap0 viruses (17, 18, 21–23). However, recent phylogenetic analysis has concluded 
that murine Ifit1 and human IFIT1 are not orthologous and these proteins have different antiviral activity 
against cap0 and cap1 viruses (4). Indeed, while human IFIT1 can bind to cap1-RNA with low affinity (8, 
13), murine Ifit1 lacks any cap1 binding activity (4, 16). 
 
Not only has IFIT1 been lost in mice and related mouse-like rodents, including model organisms such as 
the Norway rat and Chinese hamster, but IFIT5 is also absent (4). Instead, these species typically harbour 
multiple copies of the Ifit1b gene. In mice, Ifit1b has been duplicated twice, yielding three paralogues: Ifit1, 
Ifit1b and Ifit1c (Figure 1A) (also called Ifit1b1, Ifit1b2 and Ifit1b3, to reflect their evolutionary 
relatedness) (4). Despite the high degree of sequence identity between these paralogues, their functions 
remain unknown and there is little evidence supporting their expression in mouse cells. In these species, 
Ifit3 has also undergone a 3′ truncation and lacks the potential to interact with murine Ifit1 (4, 13, 14). 
Therefore, rodent Ifits may have alternative mechanisms to regulate their expression and function which 
are distinct from the human IFIT complex.  
 
In this study, we investigated the expression and activity of the entire murine Ifit family. We verified 
expression of non-canonical family members Ifit1b, Ifit1c and Ifit3b in murine cells, and found that Ifit1b 
binds to cap1-RNA with remarkable affinity and specificity. Ifit1b selectively inhibited cap1-RNA 
translation and restricted the replication of wildtype mouse coronavirus in vitro. We then established the 
different Ifit complexes which can form in mice and found that Ifit1c acts as a cofactor to Ifit1 and Ifit1b, 
promoting their stability and translation inhibition activity, thereby fulfilling a role analogous to human 
IFIT3. As such, this study helps to elucidate the ways in which primates and rodents have developed 
convergent roles for IFIT proteins in the innate immune response which occupy their same functional niche. 
We additionally highlight key distinctions between the human and murine IFIT families, in the hope that 
this will inform use of mouse models in understanding IFIT biology and antiviral activity.  
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Results 
 
Ifit1b, Ifit1c and Ifit3b are expressed in murine cells following stimulation 
 
To date, a systematic and quantitative examination of the induction kinetics of the entire murine Ifit family 
has not been carried out. While the expression patterns of murine Ifit1, Ifit2 and Ifit3 have been examined 
in detail (24–27), the expression of the other three members of the murine Ifit family, Ifit1b, Ifit1c and 
Ifit3b, has yet to be formally verified in mouse cells. To address this, murine Ifit expression was examined 
in RAW264.7 macrophage-like cells, 17Cl-1 immortalised fibroblasts and murine embryonic fibroblasts 
(MEF). Cells were stimulated with recombinant IFNb or transfected with synthetic dsRNA (polyI:C) for 
up to 48 hours. Cell lysates were examined by RT-qPCR and immunoblot analysis, using qPCR primers 
(Figure S1) and antibodies (Figure S2) specific to each murine Ifit family member. Since Ifit3 and Ifit3b 
differ by only 5 amino acids, it was not possible to differentiate between these proteins by immunoblotting 
so, to reflect this, this band will be annotated as Ifit3/3b.  
  
Consistent with previous reports (25, 26), Ifit1, Ifit2 and Ifit3 mRNA expression was rapidly induced 
following stimulation of RAW264.7 cells, with peak expression observed at 3 to 6 hours post stimulation 
(Figure 1B, Figure S3A). Expression decreased between 9-24 hours post stimulation. Ifit1, Ifit2 and Ifit3/3b 
proteins were detectable 6-12 hours following stimulation, just after the peak of mRNA expression (Figure 
1D). Ifit mRNA expression was induced to a lesser extent in 17Cl-1 fibroblast cells and expression was 
delayed compared to expression in RAW264.7 cells, with peak mRNA expression at 12-24 hours post 
stimulation (Figure 1C, Figure S3B). Similarly, at the protein level, Ifit1, Ifit2 and Ifit3/3b were detectable 
at 24-48 hours post stimulation (Figure 1E), slightly later than in the RAW264.7 cells. In MEFs, the Ifit 
mRNA induction patterns were similar to RAW264.7 cells, though the magnitude of induction was 10- to 
100-fold lower, and expression had largely returned to baseline by 24 to 48 hours post stimulation (Figure 
S3C). In both 17Cl-1 cells and MEFs, induction of Ifit2 expression was lower compared to RAW264.7 
cells, indicating that Ifit2 may be regulated differently in fibroblasts compared to macrophages (Figure 1- 
compare D and E, and Figure S3). 
 
mRNA expression was observed for Ifit1b, Ifit1c (Figure 1B,C) and Ifit3b (Figure S3) following stimulation 
and could be verified by Sanger sequencing of the qPCR product (Figure S1). While Ifit3b expression was 
strongly induced following stimulation, Ifit1b and Ifit1c were poorly upregulated, with only 10- to 100-fold 
induction over baseline in all cell lines tested. We tested a number of antibodies to confirm Ifit expression 
at the protein level. A commercially available antibody against human IFIT1 was cross-reactive with murine 
Ifit1, but detected Ifit1b to a greater extent (Figure S2B). This antibody could detect a signal in IFN-
stimulated mouse cells, but since it reacted with both Ifit1 and Ifit1b, the identity of this signal was 
ambiguous. A peptide-raised antibody against Ifit1b detected Ifit1b without cross-reactivity with Ifit1 
(Figure S2A) with greater sensitivity (Figure S2C). Using this antibody, in 17Cl-1 cell lysates, Ifit1b was 
detectable at the protein level 48 hours (Figure 1E) and 80 hours (Figure S2D) post IFN stimulation. A 
peptide-raised antibody against Ifit1c was highly specific for recombinant Ifit1c protein but could not 
reproducibly detect endogenous Ifit1c in stimulated mouse cells (Figure S2A).  
5 
To investigate the reason behind the poor expression of Ifit1b and Ifit1c in murine cells, the promoter 
regions of Ifit1, Ifit1b and Ifit1c were examined. Ifit1 has two well-defined tandem interferon stimulated 
response elements (ISRE) within 100bp of the transcription start site (TSS) (Figure S4A). The Ifit1c 
promoter region contains one canonical ISRE sequence proximal to the TSS, and a second ISRE-like 
sequence further upstream. For Ifit1b, there are two annotated TSS: one proximal to the coding sequence 
of Ifit1b (here designated Ifit1b_1) and one several kilobases upstream (Ifit1b_2), which overlaps the Ifit1 
promoter region (Figure 1A), both of which contain poorly-conserved ISRE-like sequences (Figure S4A).  
 
Promoter plasmids were designed to express firefly luciferase (Fluc) under the control of the murine Ifit 
promoters. The promoter sequence was defined as 0.8-1 kb upstream of the transcription start site (TSS) 
for each Ifit gene. A control plasmid was also generated with 1 kb of scrambled DNA sequence upstream 
of the Fluc mRNA (SCR). Promoter plasmids were co-transfected into 17Cl-1 cells alongside a constitutive 
Renilla luciferase (Rluc) expression plasmid. After 4 hours, cells were treated with IFNb to stimulate 
promoter activity, then harvested after 24 hours to determine luciferase expression. Luciferase activity was 
normalised to the Rluc control for each condition. 
 
As expected, luciferase production from the Ifit1 promoter was strongly stimulated by treatment with IFNb 
(Figure S4B). For Ifit1b, the upstream Ifit1b_2 promoter weakly drove Fluc expression but was not IFN 
responsive, while the downstream Ifit1b_1 promoter was slightly stimulated in response to IFNb. Similarly, 
the Ifit1c promoter showed a small degree of upregulation when cells were treated with IFNb (Figure S4B). 
Therefore, the lower expression of Ifit1b and Ifit1c at the mRNA level, described above, may be due to 
poorly IFN-responsive promoter sequences. 
 
Ifit1b specifically inhibits translation of cap1 mRNA. 
 
We next sought to examine the effect of the murine Ifit proteins on translation, using an in vitro translation 
assay system, which we have previously used to examine the effect of human IFIT heterocomplexing on 
their function (14). An Fluc reporter mRNA flanked by the 5′ and 3′ untranslated regions of human β-globin 
(Globin-Fluc) was transcribed and capped in vitro (Figure 2A,B). The efficiency of cap methylation was 
verified using a primer extension inhibition assay, based on the propensity of reverse transcriptase to 
terminate at methylated nucleotides, dependent on Mg2+ concentration (28, 29). Reverse transcription was 
carried out using AMV reverse transcriptase in the presence of a range of Mg2+ concentrations. At high 
Mg2+ concentrations, full-length signal was present for all mRNAs, as well as a proportion of 1 nt longer 
cDNAs, consistent with low-level terminal transferase activity (29). At lower Mg2+ concentrations however, 
1 or 2 nt shorter cDNA products were predominant for cap1 and cap2 RNA, respectively. At very low Mg2+ 
concentrations, only the lower band was detectable for cap1 and cap2 RNA, but not for cap0 RNA. This 
indicates high cap methylation efficiency, since no residual full-length signal was detectable (Figure 2B). 
  
Murine Ifit proteins were expressed and purified as described in the Materials and Methods, with the 
exception of Ifit1c, which was poorly expressed and insoluble in vitro. Ifit proteins were normalised by 
western blotting against the C-terminal His8-tag (Figure 2C). Globin-Fluc reporter mRNAs were incubated 
with 500 nM recombinant Ifit protein before the addition of RRL and translation was quantified by 
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measuring luminescence from the Fluc reporter, normalised to the buffer only control. Consistent with 
previous reports (4, 13, 16), Ifit1 strongly inhibited translation of the cap0 reporter, but could not inhibit 
cap1 or cap2 translation (Figure 2D). Translation from the uncapped reporter mRNA was much less 
efficient than any of the capped RNAs but was not reproducibly inhibited by any Ifit protein tested (Figure 
2D, left panel). Ifit2, Ifit3 and Ifit3b did not inhibit translation of any of the RNAs tested, consistent with 
the described activities of human IFIT2 and IFIT3 (5, 11, 12). However, Ifit1b strongly inhibited the 
translation of cap1 Globin-Fluc RNA, but had no effect on cap0- or cap2-RNA translation (Figure 2D).  
 
Ifit1b inhibits wildtype mouse coronavirus translation 
 
To investigate Ifit1b cap1-RNA translation inhibition in more detail, titration experiments were performed 
using the Globin-Fluc reporter, or reporters with viral 5′ and 3′UTRs flanking the same Fluc ORF (Figure 
3A). Representative species of coronavirus (mouse hepatitis virus, MHV) and flavivirus (ZIKV) were 
chosen, which have different degrees of RNA secondary structure at their 5′ ends (Figure S5). Serial 
dilutions of Ifit1b were incubated with Fluc mRNAs bearing differentially methylated 5′ caps, and 
luciferase activity was used to monitor translation in RRL, as previously. 50% inhibitory concentrations 
were interpolated from the data and are presented in Table 1. Consistent with its described cap0-RNA 
binding activity, Ifit1 caused a dose-dependent inhibition of cap0 globin-Fluc mRNA translation (IC50 = 
102 nM, Figure 3B, dotted line). Ifit1b inhibited cap1 Globin-Fluc translation at low concentrations, 
comparable to inhibition of cap0 mRNA by Ifit1 (IC50 = 152 nM, Figure 3B, red line). However, even at 
the highest concentrations of Ifit1b tested, there was still a low level of cap1-RNA translation, compared to 
complete inhibition of cap0-RNA translation by Ifit1. Ifit1b only weakly inhibited cap0 and cap2 Globin-
Fluc translation (IC50 ~ 675 nM and ~ 825 nM, respectively).  
 
MHV-Fluc mRNA was slightly more susceptible to translation inhibition by Ifit proteins. Ifit1 inhibited the 
translation of cap0-MHV-Fluc RNA at 1.6-fold lower concentrations compared to inhibition of cap0-
Globin-Fluc (IC50 = 68 nM, Figure 3C, dotted line). Likewise, Ifit1b inhibited the translation of cap1-MHV-
Fluc RNA at 1.5-fold lower concentrations compared to cap1-Globin-Fluc RNA (IC50 = 101 nM, Figure 
3C, red line). Inhibition of the cap0-MHV reporter by Ifit1b was similar to the inhibition of the cap0-Globin 
reporter (IC50 ~ 690 nM), supporting specificity for cap1-RNA binding over cap0. However, inhibition of 
cap2-MHV mRNA was slightly greater, indicating looser binding specificity to this reporter (IC50 = 238 
nM). Therefore, the sequence or structure of MHV mRNA may alter cap-binding specificity, as well as 
affinity.  
 
By contrast, ZIKV-Fluc mRNA translation was resistant to both Ifit1 and Ifit1b, even at micromolar 
concentrations (Figure 3D). At the highest concentrations of Ifit1 or Ifit1b tested, ZIKV-Fluc translation 
was inhibited by a maximum of 30-50% by either Ifit1 or Ifit1b. We have previously shown that human 
IFIT1 could completely inhibit the translation of the same cap0 ZIKV-Fluc reporter at nanomolar 
concentrations, and could inhibit cap1 ZIKV-Fluc translation at micromolar concentrations (14). Therefore, 
the inability of murine Ifit proteins to inhibit the translation of the same reporter mRNA is quite surprising.  
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Since Ifit1b could strongly inhibit the translation of cap1 MHV-Fluc reporter mRNAs, we reasoned that 
Ifit1b may be capable of inhibiting the lifecycle of (‘restricting’) MHV in cell culture. To investigate this, 
plasmids encoding mCherry-tagged Ifit1, eGFP-tagged Ifit1b or eGFP alone were electroporated into 17Cl-
1 mouse fibroblast cells, which are permissive for MHV infection (30). After 24 hours, cells were infected 
with wildtype MHV strain A59 (genome structure shown in Figure 4A, upper panel) at an MOI of 0.05 
pfu/cell. After 16 hours, cells were harvested for immunofluorescence or flow cytometry analysis 
(experimental timeline shown in Figure 4A, lower panel).  
 
Cells on coverslips were fixed and stained for double-stranded RNA, a well-described marker for RNA 
virus replication complexes (31). In empty vector or eGFP-transfected cells, 14 hours after infection with 
MHV the majority of cells showed dsRNA staining in the cytoplasm, while dsRNA was not visible in 
uninfected cells (Figure 4B). eGFP-expressing cells were positive for dsRNA, indicating that 
overexpression of eGFP had no effect on viral replication. Similarly, many mCherry-Ifit1 expressing cells 
were also positive for dsRNA signal, indicating that Ifit1 is not directly antiviral (Figure 4B, white 
arrowheads), though the dsRNA signal appeared to be lower in the cell population. By contrast, few cells 
overexpressing eGFP-Ifit1b were positive for dsRNA, implying a direct antiviral effect of Ifit1b on 
coronavirus infection (Figure 4B, open arrowheads). 
 
To quantify restriction by Ifit1b, 17Cl-1 cells were electroporated with Ifit expression plasmids and infected 
with MHV, as previously, then fixed in suspension and stained for dsRNA, before analysis by flow 
cytometry (see Figure S6). Before infection, fluorescent protein expression was checked by microscopy at 
20 hours post electroporation and transfection efficiency was comparable between plasmids (Figure S6A). 
The eGFP-Ifit1b-transfected cell population had much lower dsRNA signal compared to empty vector or 
eGFP-transfected cells, indicating that it was resistant to infection with MHV (Figure 4C). Importantly, 
cells transfected with a mutant of Ifit1b which does not bind to cap1-RNA (Ifit1b-WM, described further 
in Figure 6) were infected to the same extent as eGFP- or empty vector-transfected cells, indicating that 
Ifit1b restricts MHV infection in a manner dependent on its RNA-binding activity. eGFP-Ifit1b and eGFP-
Ifit1b-WM expression was equivalent when analysed by flow cytometry (Figure S6C). Therefore, these 
data support an antiviral role for Ifit1b in MHV infection and correlates with an inhibition of viral 
translation by binding to the cap1-RNA genome.  
 
By contrast, infection of mCherry-Ifit1-transfected cells was similar to infection of empty vector-
transfected cells, indicating that Ifit1 does not inhibit MHV infection in these cells (Figure S6E). This is 
consistent with the inability of Ifit1 to bind to cap1-RNA. However, we have previously observed that 
murine Ifit1 may promote type I IFN expression in mouse cells and thereby restrict mouse norovirus 
infection (32). Since 17Cl-1 cells respond slowly to dsRNA (see Figure 1) and do not upregulate ISG 
expression during acute MHV infection (33), this may explain why we did not observe an antiviral 
phenotype for Ifit1 in this cell type. 
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Ifit1b regulates host translation 
 
It has been estimated that between 30-70% of mouse mRNA transcripts have cap1 5′ ends, with the 
remainder bearing cap2 (34), while cap0 5′ ends are undetectable in various human and mouse cells (35). 
Therefore, we hypothesised Ifit1b should be capable of inhibiting the translation of a proportion of host 
mRNA transcripts. To investigate this, a puromycylation labelling approach was taken (36). Puromycin is 
an antibiotic which mimics the structure of aminoacylated tRNA and is thus incorporated into the nascent 
polypeptide chain during elongation, resulting in premature chain termination. When mammalian cells are 
treated with low concentrations of puromycin, it is stochastically incorporated towards the C-termini of 
nascent polypeptides. Using antibodies raised against puromycin, these labelled proteins can be detected 
by western blotting, thereby allowing visualisation of the nascent proteome of the treated cell. 
 
Murine 17Cl-1 fibroblast cells were transfected with FLAG-tagged Ifit1 or Ifit1b for 16 hours before 
treatment with 5 µg/mL puromycin for a further 4 hours. Cell lysates were separated by SDS-PAGE and 
transferred to nitrocellulose membranes, which were stained with REVERT total protein stain to ensure an 
equal quantity of lysate was loaded in each well (Figure S7). Membranes were then analysed by 
immunoblotting, using a monoclonal antibody against puromycin. Cells overexpressing Ifit1b showed a 
30% reduction in puromycin incorporation, compared to the empty vector control, indicating that Ifit1b can 
indeed inhibit a proportion of cellular translation (Figure S7). Cells overexpressing Ifit1 showed similar 
levels of incorporation to empty vector-transfected cells, indicating little effect on cellular translation.  
 
Ifit1b binds specifically to cap1 RNA. 
 
Ifit1b has previously been hypothesised not to bind to RNA since it has residues in the cap-binding pocket 
and RNA-binding channel which could disrupt association with RNA, based on structural and mutational 
analysis of human IFIT1 (8). Therefore, we wanted to determine whether inhibition of cap1 translation by 
Ifit1b was due to RNA binding or a different mode of action. Previously, we have used a primer extension 
inhibition approach to determine the RNA binding affinity of IFIT proteins. However, unlike Ifit1, Ifit1b-
RNA binding could not be visualised by primer extension (Figure S8).  
 
As an alternative approach, a thermal stability assay was developed to examine Ifit1b-RNA binding. This 
technique employs a dye which fluoresces when it binds to hydrophobic patches exposed as a protein 
unfolds, to quantify protein melting temperature (37). Binding to a substrate can increase the thermal 
stability of proteins, resulting in an increase in a melting temperature which correlates with its binding 
kinetics (38). Since it is known that IFIT proteins adopt more stable ‘closed’ conformations upon RNA 
binding (7), we reasoned that RNA binding should stabilise Ifit melting temperature.  
 
Ifit proteins were melted in the presence of increasing concentrations of an RNA oligonucleotide, 
comprising the first 25 nucleotides of the human β-globin 5′UTR (globin25), which is predicted to be 
unstructured (Figure 5A). A short oligonucleotide was chosen to minimise nonspecific stabilisation, for 
example resulting from interactions between the body of the RNA and the surface of the Ifit protein. 
Globin25 oligonucleotides were purified by size exclusion chromatography to remove small molecule 
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contaminants and capping efficiency was confirmed by high resolution denaturing PAGE (Figure 5B). 
Since both specific and non-specific binding can contribute to protein stabilisation, heterologous yeast 
tRNA was included as a blocking agent, such that only specific, high-affinity interactions which are 
sufficient to displace bound tRNA produce a signal above baseline. 
 
Increasing concentrations of cap0 RNA resulted in a dose-dependent stabilisation of Ifit1, as expected 
(Figure 5C). Cap1 RNA did not stabilise Ifit1, but actually slightly reduced Ifit1 melting temperature 
(Figure 5C). Consistent with the translation inhibition assays, Ifit1b was stabilised in a dose-dependent 
manner by cap1-globin25 RNA, indicative of binding (Figure 5D). Stabilisation by cap0-globin25 RNA 
was lower, supporting specific binding to cap1-RNA over cap0-RNA.  
 
To investigate the mechanism of RNA binding by Ifit1b, we generated a panel of point mutants based on 
homology modelling (see Methods) with the human IFIT1/cap0 RNA structure (Figure 6A). The mutant 
proteins were purified and normalised by immunoblotting against the C-terminal His8 tag (Figure 6B). 
These were then incubated with a two-fold molar excess of cap0- or cap1-globin25 RNA, before thermal 
stability analysis. Mutation of a conserved tryptophan residue, W152, which is necessary for cap guanosine 
coordination by human IFIT1 (8), reduced stabilisation of Ifit1b by cap1-RNA back to background levels 
(Figure 6C). Mutation of the charged residues in the cap-binding loop had little effect on cap1-RNA 
binding. Mutation of E50 to alanine or glutamine only slightly reduced cap1 RNA binding, while mutation 
of R54 to alanine or leucine reduced stabilisation by cap1 RNA by about half. Mutation of both E50 and 
R54 to the equivalent residues in Ifit1, and conserved in human IFIT1 (glutamine and leucine, respectively), 
restored cap1 binding back to wildtype levels (Figure 6C). Previously, in human IFIT1, mutation of these 
residues to alanine only slightly reduced cap0-RNA binding (8), indicating that they contribute to stable 
cap binding but their exact identity is not critical. We also observed a slight increase in cap0-RNA binding 
by the E50A and E50Q/R54L mutants, indicating they may impact RNA binding specificity, even though 
these residues do not contact the first RNA nucleotide (Figure 6D, left panel). Together this indicates that 
Ifit1b likely engages the cap using the conserved tryptophan-144 residue but the other face of the cap-
guanosine is coordinated non-specifically, in this case by long, polar side-chains in the cap-binding loop, 
which may impact cap-binding specificity. 
 
Next, mutations were made within the RNA binding channel to investigate how Ifit1b achieves specific 
cap1 RNA binding. In human IFIT1, the residues immediately proximate to the ribose 2′-hydroxyl group, 
Y157 and R187, sterically hinder binding to 2′-O-methylated RNA (8) (Figure 6D, right panel). In murine 
Ifit1b the tyrosine is conserved at position 162, but the arginine residue is substituted for H192. Therefore, 
H192 was investigated for its contribution to RNA methylation sensing, by mutation to alanine, arginine or 
glutamate. Mutation to alanine reduced stabilisation by cap1 RNA by half, while mutation to glutamate had 
no effect on cap1-RNA binding. However, H192E increased stabilisation of Ifit1b by cap0 RNA by two-
fold, indicating that H192 may indeed play a role in discriminating RNA methylation state (Figure 6C. 
Mutation of H192 to arginine, mimicking human IFIT1 and murine Ifit1, abrogated RNA binding entirely. 
However, Ifit1b H192R was less stable than wildtype Ifit1b, indicating that H192R may disrupt the correct 
folding of Ifit1b, accounting for the loss of RNA binding activity. The reciprocal in human IFIT1 (R187H) 
similarly abolished cap0-RNA binding (8). 
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Murine Ifit proteins form heterodimeric complexes. 
 
We and others recently reported that the interaction between human IFIT1 and IFIT3 is important for 
regulation of IFIT1 activity (13–15). However, murine Ifit3 cannot interact with murine Ifit1 (13, 16), due 
to a genetic truncation in mouse-like rodents, which deletes the region of the protein responsible for IFIT1 
interaction (Figure S9). However, the C-terminal YxxxL motif, critical for human IFIT1-IFIT3 complex 
formation, is conserved in murine Ifit1, Ifit1b and Ifit1c, indicating that these proteins may be capable of 
hetero-complexing (Figure 7A, S10). 
 
We first examined the oligomeric state of Ifit proteins in solution. Human IFIT1 was recently described to 
homodimerise in a concentration-dependent manner, via the C-terminal YxxxL motif (39). BSA, which is 
a 65 kDa monomer with a small proportion of 132 kDa dimeric species, was used as a size marker for size 
exclusion chromatography (SEC). When analysed by SEC, Ifit1 and Ifit1b eluted after the BSA dimer but 
before the BSA monomer peak, indicating that these proteins are homodimers (Figure S11A,B). This was 
confirmed for Ifit1b, which had the molecular weight of a dimer when analysed by SEC coupled with multi-
angle light scattering (SEC-MALS) at different concentrations (Figure S11C). When the YxxxL motif was 
mutated in either Ifit1 or Ifit1b, the mutant proteins eluted later on the SEC column, after the BSA monomer, 
indicating that they are indeed monomeric (Figure S11A,B). When analysed by SEC, MBP-Ifit1cCTD eluted 
in the void fraction, consistent with the poor stability of this protein and its tendency to aggregate, and so 
was not suitable for SEC-MALS analysis. 
 
To investigate which murine Ifit proteins can interact with each other, an in vitro co-precipitation assay was 
used, similar to that employed by Johnson et al (2018) for the interrogation of human IFIT interactions. 
Equimolar MBP-tagged bait and His-tagged prey proteins were incubated together at 30˚C for one hour, 
before precipitation on amylose resin. Ifit3 was included as a negative control in each experiment and, 
consistent with a recent report (13), did not co-precipitate with any of the baits tested (Figure 7B-D). MBP-
Ifit1 precipitated both Ifit1b and Ifit1 (Figure 7B and S12A), while MBP-Ifit1b precipitated both Ifit1 and 
Ifit1b (Figure 7C, Figure S12B), indicating that Ifit1 and Ifit1b are capable of heterocomplexing. When 
Ifit1 and Ifit1b were incubated together and analysed by SEC, the eluting species was the same size as the 
Ifit1 or Ifit1b homodimers, and higher order species were not detected (Figure S11D). MBP alone did not 
interact with Ifit1b or Ifit3 (Figure 7B, lower panel), but pulled down a trace amount of Ifit1 (Figure 7C, 
lower panel). Since Ifit1 had a tendency to precipitate during this assay, this likely represents nonspecific 
binding of Ifit1 to the MBP or to the beads themselves.  
 
To determine whether Ifit1 or Ifit1b could interact with Ifit1c, full-length MBP-tagged Ifit1c was used as 
bait. Recombinant full-length Ifit1c was highly unstable and, despite exhaustive efforts, refractory to 
purification. MBP-tagged Ifit1c was soluble but was nevertheless highly impure (Figure S12C,D). 
However, despite the contaminants present in the recombinant MBP-Ifit1c, Ifit1b was clearly visible in the 
precipitate, indicative of an interaction (Figure S12D). Owing to the presence of a contaminant band in 
Ifit1c at the same molecular weight as Ifit1, this interaction was more difficult to confirm (Figure 12C). To 
circumvent this, a truncated MBP-tagged Ifit1c construct was generated, containing the three most C-
11 
terminal TPRs (MBP-Ifit1cCTD, amino acids 338-470, Figure S12E), which allowed purification of clean 
recombinant Ifit1c for use as bait. Ifit1 and Ifit1b both precipitated with MBP-Ifit1cCTD, while Ifit3 did not 
(Figure 7D). Therefore, Ifit1c can specifically form complexes with both Ifit1 and Ifit1b via its C-terminal 
domain. 
 
The relative affinity of these interactions was investigated by competitive co-precipitation experiments. 
MBP-tagged Ifits were used as bait, and incubated with prey protein at 30 ˚C before binding to amylose 
resin, as previously. Beads were then washed with increasing concentrations of a competitor prey protein, 
with the expectation that higher affinity interactions should displace lower affinity ones. However, we 
observed that even high concentrations of Ifit1b could not disrupt the interaction between Ifit1 and MBP-
Ifit1cCTD (Figure S12F), and likewise Ifit1 did not disrupt the Ifit1b-MBP-Ifit1cCTD complex (Figure S12G). 
Next, MBP-Ifit1cCTD was incubated together with both Ifit1 and Ifit1b, at different temperatures. When 
incubated together on ice MBP-Ifit1cCTD coprecipitated both Ifit1 and Ifit1b, to a similar extent (Figure 
S12H). Since this interaction occurred even at low temperatures, it indicates that heterocomplexing is 
preferential and high affinity, but Ifit1c binds to both Ifit1 and Ifit1b with comparable affinity. Slightly 
more Ifit1 coprecipitated with MBP-Ifit1cCTD when the proteins were incubated at 30 ˚C (Figure S12I), 
which may be indicative of aggregation, rather than true preferential interaction, as we observed with MBP-
only (see Figure 7C, lower panel). Therefore, these experiments indicate that purified Ifit1c can interact 
with both Ifit1 and Ifit1b to a similar extent, and these interactions are preferential over homodimerisation. 
 
Heterocomplexing enhances Ifit stability in vitro. 
 
We previously observed that functionally important human IFIT heterocomplexes were more stable than 
IFIT proteins in isolation, both in vitro and in human cells (14). Therefore, we analysed the thermal stability 
of murine Ifit proteins and complexes using differential scanning fluorimetry. Ifit proteins were incubated 
alone or in combination for 30 minutes on ice, then assayed for thermal stability, as described above for the 
Ifit1b RNA binding assay. Full length Ifit1c could not be used due to the high degree of contaminants 
present, so instead the C-terminal fragment of Ifit1c was analysed. Ifit1cCTD was expressed without an MBP 
tag, since MBP is very stable and would interfere with the melt curve analysis.  
 
Murine Ifit1 and Ifit1b alone were relatively unstable, with melting temperatures around physiological 
temperature (Figure 7E, Table 2). For comparison, MBP had a melting temperature of 60 °C when analysed 
under the same conditions (Figure 7E, dashed line). When Ifit1 and Ifit1b were mixed together, the melt 
curve was intermediate between the melting temperatures of the constituent proteins, indicating that this 
interaction does not provide any stability to either protein (Figure 7E). Ifit1cCTD alone was very unstable 
and did not produce a quantifiable melt curve. However, when either Ifit1 or Ifit1b was mixed with 
increasing concentrations of Ifit1cCTD, melting temperature increased by up to 3 ˚C (Figure 7F,G Table 2). 
Therefore, interaction with the C-terminal domain of Ifit1c enhances the thermal stability of both Ifit1 and 
Ifit1b.  
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Ifit1 and Ifit1b stabilise Ifit1c expression in murine cells. 
 
Ifit heterocomplexes were then examined in mouse cells, to determine if co-expression of different murine 
Ifit proteins can stabilise their expression. To do this, plasmids were generated which expressed mCherry-
tagged Ifit1 or eGFP-tagged Ifit1b, followed by FLAG-tagged Ifit1c in the same open reading frame, 
separated by the 2A stop-go peptide sequence from thosea asigna virus. The 2A sequence efficiently skips 
a peptide bond during translation elongation, effectively cleaving the two proteins (40), allowing 
stoichiometric coexpression of Ifit proteins from the same plasmid. Ifit1c was either wildtype or had a 
mutant YxxxL (YL) motif to disrupt heterocomplexing. For consistency and clarity, in Figure 8 both 
mCherry-Ifit1 and eGFP-Ifit1b fluorescent proteins (FP) are shown in green, while FLAG-Ifit1c is shown 
in magenta (Figure 8A).  
 
Murine 17Cl-1 cells were seeded onto coverslips, then transfected with Ifit co-expression plasmids. After 
24 hours, cells on coverslips were fixed and stained for FLAG, while surrounding cells from the same well 
were harvested for western blotting. When transfected alone, FLAG-Ifit1c expression was very low (Figure 
8B,C). However, FLAG-Ifit1c expression was moderately enhanced when co-expressed with mCherry-Ifit1 
(Figure 8B) and strongly enhanced by co-expression with eGFP-Ifit1b (Figure 8C). However, when the 
YxxxL motif in Ifit1c was mutated, expression was similar to Ifit1c alone (Figure 8B,C), indicating that 
interaction with Ifit1 or Ifit1b is necessary for Ifit1c stabilisation. Neither mCherry-Ifit1 nor eGFP-Ifit1b 
expression was affected by co-expression with wildtype or mutant Ifit1c (Figure 8B,C).  
 
When analysed by microscopy, mCherry-Ifit1 or eGFP-Ifit1b expressed alone showed diffuse cytoplasmic 
localisation (Figure 8D,E, left-most panels), typical of IFIT proteins (41, 42). However, when FLAG-Ifit1c 
was expressed alone, it showed punctate staining within the cytoplasm, with few cells showing diffuse 
localisation (Figure 8D, top-right panel). These puncta did not significantly colocalise with a proteasome 
marker and did not aggregate at the proteasome when cells were treated with the proteasome inhibitor MG-
132 (Figure S13A). FLAG-Ifit1c expression was also not rescued upon MG-132 treatment (Figure S13B). 
 
When wildtype FLAG-Ifit1c was co-expressed with either mCherry-Ifit1 or eGFP-Ifit1b, both proteins 
localised in the cytoplasm and very few cells showed punctate staining for Ifit1c (Figure 8D, centre bottom 
and 8E, centre). Ifit1c expression also appeared to be higher, evident from the brighter fluorescence signal, 
consistent with the western blotting data (compare Figure 7D, top right to 7D centre bottom). When FLAG-
Ifit1c-YL was co-expressed with mCherry-Ifit1 or eGFP-Ifit1b, cells still expressed both signals in the 
cytoplasm. However, co-localisation of the two signals was not as consistent as for wildtype Ifit1c and 
many cells still showed punctate FLAG staining (Figure 7D, right bottom and 7E, right). The fluorescence 
signal was also weaker for FLAG in these cells, indicating lower Ifit1c expression. Therefore, interaction 
between Ifit1 or Ifit1b and Ifit1c may relocalise Ifit1c within the cytoplasm and stabilise its expression. 
 
The C-terminal domain of Ifit1c stimulates translation inhibition by Ifit1 and Ifit1b. 
 
Next, we sought to determine whether Ifit1c could act as a cofactor for Ifit1 or Ifit1b, by determining 
translation inhibition activity of Ifit complexes in vitro. Increasing concentrations of Ifit1 or Ifit1b were 
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incubated with cap0 or cap1 MHV-Fluc reporter mRNAs (Figure 9A), in a reaction containing RRL with 
or without the addition of 500 nM MBP-Ifit1cCTD. Luciferase signal was measured, as previously, and 
normalised to the buffer-only or MBP-Ifit1cCTD-only condition for each titration series. IC50 values from 
these experiments are given in Table 3. 
 
Inclusion of MBP-Ifit1cCTD in the translation reaction decreased the concentration of Ifit1 required to cause 
a 50% decrease in translation from cap0 MHV-Fluc reporter mRNA by 5-fold (Figure 9B). Similarly, 
addition of MBP-Ifit1cCTD decreased the IC50 of Ifit1b on cap1 MHV-Fluc mRNA by 5-fold (Figure 9C). 
MBP-Ifit1cCTD also enhanced translation inhibition by Ifit1b at higher concentrations, allowing almost 
complete inhibition of translation, suggesting that Ifit1c may promote saturation of RNA binding by Ifit1b. 
Addition of mutant MBP-Ifit1cCTD-YL did not enhance translation inhibition, indicating that interaction 
between Ifit1 or Ifit1b and Ifit1c is necessary for Ifit1c cofactor activity (Figure 9B,C). When human IFIT3 
was added to a translation reaction with human IFIT1, inhibition of cap0-MHV-Fluc translation was 
enhanced, as we previously described (14). By comparison, addition of Ifit1cCTD did not affect translation 
inhibition by human IFIT1 (Figure 9D). Together this indicates that Ifit1c can specifically act as a cofactor 
for both Ifit1 and Ifit1b to enhance their translation inhibition activity. 
 
Discussion 
 
IFIT proteins play extensive and diverse roles not only in antiviral defence, but also in inflammation, cancer 
and autoimmunity (reviewed in (15, 43, 44)). Studying their function in vivo is invaluable for properly 
understanding their role in modulating such complex diseases. Given the widespread use of animal models, 
particularly mice, in biomedical research, it is important to understand how their innate immune systems 
differ to that of humans in order to properly evaluate the usefulness of data generated by animal studies 
with regards to human disease. However, in recent years it has become increasingly clear that the human 
and murine IFIT families differ in key aspects both in terms of their function and their regulation. 
 
Human IFIT1 is well characterised to bind to cap0-RNA in vitro and inhibit its translation (8, 11, 16). As 
such, human IFIT1 can restrict viruses which produce cap0 mRNA, such as those with mutated 2′-O-
methyltransferase enzymes (21–23). These viruses are typically attenuated in mouse infection models, and 
in some cases can be partially or fully restored upon knockout of murine Ifit1 (17, 18, 21–23). Human IFIT1 
was more recently shown to bind weakly to cap1-RNA and inhibit its translation at high IFIT1 
concentrations. As such, human IFIT1 is capable of restricting the replication of viruses with cap1-RNA 
when expressed at high levels (4, 13). Murine Ifit1, however, does not share this function and can only 
inhibit cap0-RNA translation (4, 16), a finding which was recapitulated here.  
 
Instead, we found that a related protein, murine Ifit1b, could inhibit the translation of cap1-RNA at 
nanomolar concentrations but failed to inhibit cap0 or cap2 translation. We show that overexpression of 
Ifit1b can inhibit the translation of mouse coronavirus model RNAs, while restricting viral replication in 
murine cells. Previously, overexpression of murine Ifit2 was shown to slightly inhibit the replication of 
both WT and cap0-mutant MHV (17), while Ifit2 knockout increased replication of neurotropic MHV and 
exacerbated viral encephalitis (45). The antiviral effect of Ifit2, however, was due to an enhancement of 
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innate immune signalling, much like we reported recently for murine Ifit1 (32), rather than a direct effect 
on viral replication. Human IFIT1 can inhibit cap0-mutant strains of a number of human coronaviruses, 
while murine Ifit1 can inhibit cap0-mutant MHV, but neither could inhibit the replication of wildtype virus 
(21–23).  
 
This ability of Ifit1b to specifically sense cap1 methylation is quite striking. Previously, IFIT proteins have 
been identified which can bind to cap1-RNA with low affinity, particularly rabbit IFIT1B, but in all cases 
could also bind strongly to cap0-RNA (4, 8, 9, 11). Our mutational analysis implicated histidine-192 as a 
key residue in Ifit1b cap1 sensing, though the exact mechanism of cap1 discrimination remains uncertain. 
It is possible that specific contacts are made between H192 and the RNA 2′-O-methyl group itself, to 
stabilise the Ifit1b-RNA complex, allowing preferential binding to cap1 over cap0. This mechanism of 
RNA-binding has been shown previously for eIF4E5, one isoform of the cap-binding translation initiation 
factor eIF4E, from trypanosome parasites. eIF4E5 interacts with cap4-methylated mRNA, a methylation 
state unique to these parasites, by making specific contacts between certain hydrophobic sidechains and the 
methylated RNA backbone, resulting in significantly higher affinity of eIF4E5 for cap4- over cap0-RNA 
(46).  
 
While the translation of unstructured RNAs was efficiently inhibited by murine Ifit1 and Ifit1b, here it was 
found that neither protein was capable of inhibiting the translation of a ZIKV reporter mRNA, even at 
micromolar concentrations. Previously we showed that human IFIT1 effectively inhibited translation of the 
same ZIKV reporter construct at nanomolar concentrations (14), indicating a fundamental difference in the 
ability of human IFIT and murine Ifit proteins to bind to the same substrate. It was previously shown that 
alphaviruses have a very stable stem loop at the immediate 5′ end of the genome, which prevents binding 
by mouse Ifit1 and confers resistance to type I IFN in vivo (47, 48). Destabilising this RNA secondary 
structure confers susceptibility to restriction by Ifit1 (47). Flaviviruses, including ZIKV, have a comparable 
stable stem loop at the very 5′ end of their genomes (49) (Figure S5), indicating that they, too, may be 
refractory to binding by murine Ifit proteins for the same reason.  
 
Such differences in the ability of human IFIT1 and murine Ifits to bind RNA with strong 5′ structure may 
have implications for vaccine development. In a mouse model of West Nile virus (WNV) infection, a 
Flavivirus closely related to ZIKV, Ifit1 knockout did not restore attenuation of a cap0-mutant WNV strain 
in some tissues and in primary cultures derived from Ifit1 knockout mice (18). Furthermore, even though 
Ifit1 is expressed throughout the brain following WNV infection (50), WNV infection in the central nervous 
system was unaffected by Ifit1 knockout (18). However, both murine Ifit1 and human IFIT1 can restrict 
cap0-mutant WNV replication in certain cell lines (13, 17, 18) Differences in the expression or activity of 
IFIT proteins in different tissues between humans and mice may have major implications for the safety and 
efficacy of a cap0 WNV vaccine strain.  
 
Recently, we and others described a functional complex between IFIT1 and IFIT3 in humans, in which 
IFIT3 acts as a cofactor to stabilise IFIT1 expression and enhance its RNA binding activity (13, 14). 
However, in murid rodents, Ifit3 is truncated and lacks the C-terminal domain containing the YxxxL IFIT1 
interaction motif and thus cannot interact with Ifit1 (13) (see Figure S9), a finding that was recapitulated 
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here. However, murine Ifit1, Ifit1b and Ifit1c maintain the YxxxL motif at the C-terminus and we found 
that these proteins can interact, likely as heterodimers. Like human IFIT complexes, interaction between 
murine Ifit proteins was shown to increase their thermal stability, suggesting heterocomplexing is a 
thermodynamically preferable state. In mouse cells, Ifit1c expression was significantly enhanced by co-
expression with Ifit1 or Ifit1b. In vitro, the C-terminal domain of Ifit1c was sufficient to enhance translation 
inhibition by Ifit1 and Ifit1b, similar to the enhancement we observed previously for the human IFIT1:IFIT3 
complex (14). 
 
The mechanism by which IFIT cofactors enhance translation inhibition remains to be determined. We 
previously hypothesised that the long C-terminal domain of human IFIT3, which is extended by two a-
helices relative to IFIT1, promoted RNA binding by IFIT1 (14). IFIT3 was shown to make contacts with 
the C-terminal and pivot domains of IFIT1 (13), which suggested that IFIT3 may alter the flexibility of 
IFIT1, causing it to remain bound to cap0-RNA and thereby increasing its affinity. This, in turn, allows 
IFIT1 to more effectively out-compete eIF4E for binding to the mRNA cap, inhibiting translation initiation 
at lower IFIT concentrations. However in mice, Ifit1c does not have a long C-terminal tail which would 
allow an analogous mechanism of action, suggesting that Ifit1c may act in a different way to enhance RNA 
binding by Ifit1 and Ifit1b. This may explain why murine Ifit1c could not enhance translation inhibition by 
human IFIT1, and why human IFIT3 did not bind to murine Ifit1 in a previous study (13).  
 
The YxxxL interaction motif is almost universally conserved in mammalian IFIT1, IFIT1B and, where 
applicable, IFIT3 protein sequences (see Figure S10). Given that IFIT1 and IFIT1B are cap-RNA binding 
proteins, this proposes a situation in which the IFIT proteins which are capable of binding to capped RNA 
need to form complexes with regulatory IFIT cofactors. This may allow fine-tuned expression of IFIT 
proteins which have the potential to inhibit cellular translation (51), and therefore pose a cytotoxic risk. It 
may also be a way of integrating IFIT-RNA binding into the wider innate immune response. IFIT3 in 
humans, for example, is known to stimulate innate immune signalling by promoting the interaction between 
MAVS, an adaptor protein in the cytoplasm downstream of dsRNA sensing, and its activating kinase TBK1 
(52, 53). The impact of a heterocomplex of IFIT1 and IFIT3, bound to non-self RNA, on innate immune 
signalling has yet to be investigated. IFIT3 additionally forms a heterocomplex with the proapoptotic IFIT2, 
via a different interaction interface in the N-terminus, and decreases IFIT2-directed cell death (14, 54). 
Therefore, in humans but not in mice, the regulation of IFIT1 is intrinsically linked to the regulation of 
IFIT2, since they share a cofactor. The implications of IFIT co-regulation in innate immunity, apoptosis 
and other cellular processes are still unknown. 
 
In summary this present study, coupled with previous evolutionary analyses of the IFIT family (3, 4), has 
revealed convergent mechanisms for RNA binding and complex formation between species, even while the 
IFIT locus itself has undergone major restructuring. A model for convergent human IFIT and murine Ifit 
function is presented in Figure 10. In humans there is a single protein, IFIT1, which binds very strongly to 
non-self cap0-RNA, but may also weakly bind to self cap1-RNA, and inhibit their translation (4, 8, 11, 16). 
Human IFIT1 is highly expressed in response to IFN (12), along with its cofactor IFIT3, which promotes 
its stability and translation inhibition activity (13, 14). By contrast in mice, murine Ifit1 binds only to cap0-
RNA and is highly expressed (16), while murine Ifit1b binds strongly to cap1-RNA but is poorly expressed 
16 
in stimulated mouse cells, as we have demonstrated here. Both proteins are regulated by Ifit1c, which acts 
as a cofactor analogous to human IFIT3. In this way, murine and human cells may achieve the same balance 
of cap0- and cap1-RNA binding during the IFN response. Therefore, considering the IFIT locus together, 
rather than examining individual genes, could be more valuable in examining IFIT molecular function.  
 
Experimental procedures 
 
Plasmids 
Ifit promoter sequences were defined as 1 kb upstream of the annotated transcription start site for each Ifit 
gene, derived from their respective mRNA sequences (Ifit1: NM_008331.3, Ifit1b_1: NM_001362130.1, 
Ifit1b_2: NM_053217.2, Ifit1c: NM_001110517.1), except in the case of Ifit1b_2, where only 0.8 kb of 
sequence was included owing to highly repetitive DNA in the most distal 5′ sequence. Promoters were 
cloned between MluI and XhoI sites in pGL3 Basic (Promega), upstream of Firefly luciferase. pRL-TK 
(Promega) was included as a normalisation control.  
 
For reporter RNA transcription, the firefly luciferase reporter gene flanked by the 5′ and 3′ UTRs of the 
MHV N protein subgenomic mRNA, which shares 5′ and 3′ terminal sequences with all MHV mRNAs 
(NC_001846.1) was synthesised with a 5′ T7 promoter sequence (IDT) and inserted between EcoRI and 
PstI sites in pUC57. pUC57-globin-Fluc (14) and pUC57-ZIKV-Fluc (55) were previously described.  
 
For bacterial expression, sequences for murine Ifit1 (NP_032357.2), Ifit1b (NP_444447.1), Ifit1c 
(NP_001095075.1), Ifit2 (NP_032358.1), Ifit3 (NP_034631.1) and Ifit3b (NP_001005858.2) were inserted 
into pTriEx1.1 to contain a C-terminal 8xHis tag, as previously described (32). For MBP-tagged proteins, 
Ifit sequences were inserted between NdeI and BamHI sites in pOPTHM, which contains an N-terminal 
His6 tag followed by an MBP tag. pOPTHM-Ifit1cCTD was generated by PCR amplification of the C-
terminal domain of Ifit1c and pOPTH-Ifit1cCTD was generated by overlapping PCR to remove the MBP tag. 
Mutants were derived from these plasmids by site directed mutagenesis PCR using overlapping primers. 
The plasmids for expression of human IFIT1 (10) and IFIT3 (14) have been described.  
 
For mammalian cell expression, pCDNA3.1 containing Ifit sequences with an N-terminal FLAG tag were 
purchased from Genscript. For co-expression, eGFP was PCR amplified to contain a 5′ NheI site and Kozak 
sequence and 3′ NdeI and BamHI sites, followed by XbaI. This eGFP fragment was then inserted into 
pCDNA3.1 between NheI and XbaI sites. Ifit1 or Ifit1b was then inserted between the introduced NdeI and 
BamHI sites. Ifit1c was PCR amplified to contain a 5′ thosea asigna virus 2A sequence, followed by a 
FLAG tag. The 3′ end was WT or contained the YL mutation. The 5′ and 3′ sequences were engineered to 
overlap the regions flanking the pCDNA3.1-eGFP-Ifit1b BamHI site, to allow insertion by Gibson 
assembly. Since eGFP-Ifit1 did not express in mouse cells, pCDNA3.1-mCherry-Ifit1 was derived from 
pCDNA3.1-eGFP-Ifit1 by inserting the mCherry tag between NheI and EcoRI sites to replace the eGFP 
tag. Ifit1c was then inserted into the BamHI site by Gibson assembly, as previously. RNA binding mutants 
of Ifit1 (pCDNA3.1-mCherry-Ifit1WM) and Ifit1b (pCDNA3.1-eGFP-Ifit1bWM) were generated by site 
directed mutagenesis, producing W144M and W152M mutants, respectively.  
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Recombinant protein expression and purification 
Recombinant proteins were expressed in Rosetta2 (DE3) pLysS Escherichia coli cells (Novagen). Cells 
were grown to an OD600 of 0.4-1 in 2x TY medium. Protein expression was induced using 1 mM isopropyl 
b-D-1-thiogalactopyranoside, at 20 °C for 20 hours. Cells were harvested and lysed in buffer containing 
400 mM KCl, 40 mM Tris-HCl pH 7.5, 5% glycerol, 2 mM DTT, 0.5 mM PMSF and 1 mg/mL lysozyme. 
Proteins were isolated by affinity chromatography on Ni-NTA agarose resin (Qiagen) or PureCube 100 Ni-
NTA agarose (Cube Biotech). Proteins were typically polished by FPLC on Superdex 200 increase 10/300 
or HiLoad 16/600 columns (GE Healthcare), in Buffer I (200 mM KCl, 40 mM Tris-HCl pH 7.5, 5 % 
glycerol, 1 mM DTT), concentrated to > 1 mg/mL, then stored at -70 °C. Recombinant IFNb was produced 
as previously described from HEK293T cells transfected with pCDNA3-IFN-b (56). Supernatant was 
harvested after 24 hours, aliquoted, and stored at -70 °C and was diluted 1:500 in cell culture media to 
stimulate cells. 
 
In vitro transcription 
Plasmids were linearised with FspI (globin), PmlI (MHV) or HindIII (ZIKV), and purified by gel extraction 
(globin) or ethanol precipitation (MHV and ZIKV). RNA was transcribed from 0.5 – 2 µg linearised 
template using 50 ng/µL recombinant T7 RNA polymerase in transcription buffer (40 mM HEPES-NaOH 
pH 7.5, 32 mM MgOAc, 40 mM DTT, 2 mM spermidine, 10 mM ATP, 10 mM CTP, 10 mM GTP, 10 mM 
UTP, 0.2 U/µL RNaseOUT (Invitrogen)), for 2-4 hours at 37 °C. RNA was purified by DNaseI treatment, 
acidic phenol extraction and ethanol precipitation. Residual nucleotides were removed using Illustra 
MicroSpin G-50 columns (GE Healthcare). To produce cap0 and cap1 RNA, 40-60 µg RNA was capped 
using the ScripCap m7G capping system and 2′-O-methyltransferase system (CellScript). Cap2 RNA was 
generated from cap1 templates using 200 ng/µL recombinant cap2 methyltransferase in cap2 buffer (50 
mM Tris-HCl pH 7.5, 5 mM DTT, 2 mM S-adenosyl methionine, 0.1 U/µL RNaseOUT), incubated at 20 
˚C for 4 hours before acidic phenol extraction and ethanol precipitation, as described above. Residual 
nucleotides and SAM were removed using Illustra MicroSpin G-50 columns (GE Healthcare). 
 
Short RNA transcripts (5′-GACATTTGCTTCTGACACAACTGTG-3′) were transcribed from negative 
strand DNA oligonucleotide templates, containing a 3′ negative strand T7 promoter sequence (5′-
CACAGTTGTGTCAGAAGCAAATGTCTATAGTGAGTCGTATTA-3′), annealed to a T7 promoter-
containing forward primer (5′-TAATACGACTCACTATA-3′). RNA was transcribed from 5-10 µM 
annealed DNA oligos, in modified transcription buffer (500 ng/µL T7 polymerase, 40 mM HEPES-NaOH 
pH 7.5, 13.4 mM MgOAc, 40 mM DTT, 2 mM spermidine, 0.6 mM ATP, 4 mM CTP, 6 mM GTP, 0.6 mM 
UTP, and 0.1 U/µL RNaseOUT (Invitrogen)). After purification, to remove residual nucleotides, RNA was 
polished by FPLC on a HiLoad Superdex 75 pg 16/600 column (GE healthcare) in milliQ water at 4 °C, at 
a flow rate of 1 mL/min. Peak fractions were concentrated by ethanol precipitation. Up to 150 µg (~ 200 
µM) oligonucleotide RNA was capped in modified capping reactions, containing 1 mM (cap0 reactions) or 
2 mM (cap1 reactions) S-adenosyl methionine (NEB) and residual nucleotides were again removed by size 
exclusion. 
 
Denaturing PAGE 
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Short RNAs were denatured by boiling for 5 minutes at 75 °C in 50% formamide loading buffer and 
separated in 15 % acrylamide 7 M urea gels (Bio-Rad Mini-PROTEAN format) at 300 V for 35 minutes. 
Longer RNAs were separated in 6 % acrylamide 7 M urea gels at 300 V for 45 minutes. Gels were stained 
in 1x TBE containing 2 µg/mL ethidium bromide for 10 minutes, then washed twice in water before imaging 
under 302 nm ultraviolet light. 
 
Primer extension inhibition 
For the 2′-O-methylation assay, 50 ng Cy5-labelled primer (Sigma) was annealed to 40 nM RNA by heating 
to 75 °C for 5 minutes and snap-cooling on ice. Reverse transcription was carried out using 5 U avian 
myoblastosis virus (AMV) reverse transcriptase (Promega) in 20 mM Tris-HCl pH 7.5, 100 mM KCl, 0.5 
mM dNTPs with 0-4 mM MgOAc. For IFIT binding experiments, 25 ng Cy5-labelled primer was annealed 
to 10 nM RNA, then incubated with indicated concentrations of IFIT in 20 µL reactions containing 20 mM 
Tris-HCl pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 1 mM ATP, 0.2 mM GTP, 1 mM DTT, 0.25 mM 
spermidine, 0.1 U/µL RNaseOUT and 0.5 mg/mL bovine serum albumin (BSA). Reactions were incubated 
at 37 ˚C for 10 minutes before addition of 2.5 U AMV reverse transcriptase (Promega), 4 mM MgCl2, 0.5 
mM dNTPs and labelled primer, either Cy5 (Figure S8A) or 32P (Perkin-Elmer) (Figure S8D). Reverse 
transcription reactions were incubated at 37 ˚C for 30 minutes, then stopped with 100 mM EDTA and 10% 
SDS. cDNA products were extracted with UltraPure phenol:chloroform:isoamylalcohol (25:24:1) pH 8 
(ThermoFisher) and ethanol precipitated. Pellets were resuspended in 91 % formamide loading dye and 
boiled for 5 minutes at 75 °C for PAGE. cDNA products were separated by 6% denaturing PAGE on 35 
cm sequencing gels for 30-60 minutes, then imaged directly on an FLA7000 Typhoon scanner (GE). 
 
In vitro translation 
For translation inhibition assays, Ifit proteins were serially diluted in BSA buffer in a volume of 2.5 µL (20 
mM Tris-HCl pH 7.5, 150 mM KCl, 5 % glycerol, 1 mM DTT, 0.5 mg/mL BSA, 10 U/µL RNaseOUT). 
125 ng Fluc reporter RNA bearing different 5′ and 3′UTRs (15-20 nM final) was added to diluted Ifits and 
incubated at 30 ˚C for 15 minutes for RNA binding. In vitro translation was then carried out using the Flexi 
rabbit reticulocyte lysate (RRL) system (Promega) at 30 °C for 90 minutes. For murine Ifit complexes, 500 
nM MBP-Ifit1cCTD or the equivalent volume of Buffer I was included in the RRL master mix. Reactions 
were incubated at 30 ˚C for 90 minutes, then stopped by addition of 50 µL passive lysis buffer (Promega) 
on ice. Stopped translation reactions were diluted 1:10 and an equal volume of firefly luciferase assay 
reagent was added, to a final volume of 50 µL. Luminescence was measured by GloMax for 10 seconds per 
well. Data were normalised to the no IFIT control for each experiment. 50% inhibitory concentrations (IC50) 
were derived by fitting to [Inhibitor] versus normalised response curve (Y = 100)/(1 + 
(XHillSlope)/(IC50HillSlope)) using the least squares method in GraphPad Prism. Confidence intervals were 
calculated using the likelihood ratio asymmetric method and a replicates test was performed to test for lack 
of it. Curves were compared by extra sum of squares F-test. 
 
Co-precipitation 
For co-precipitation experiments, 2.5 µM MBP-tagged bait protein was incubated with 2.5 µM prey protein 
at 30 ˚C for 1 hour, in Buffer P (20 mM Tris-HCl pH 7.5, 200 mM KCl, 5 % glycerol, 0.1 % NP-40, 1 mM 
EDTA, 5 mM DTT) in a final volume of 40 µL. Proteins were centrifuged at 15,000g for 60 seconds to 
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remove any precipitate, then applied to equilibrated amylose magnetic beads (NEB) for 30 minutes, in a 
final volume of 200 µL. Beads were washed 3 times for one minute in Buffer P, then eluted by incubation 
for 20 minutes with 100 mM maltose in Buffer P. For competition assays, beads were washed once in 
Buffer P, followed by 3 washes with increasing concentrations of competitor protein (0.5, 1 and 2 µM), for 
10 minutes each. Beads were washed once in Buffer P before elution. 10 µL samples were taken at each 
stage for SDS-PAGE analysis. 
 
Differential scanning fluorimetry 
To assay RNA binding, a dilution series of 25 nt model RNAs, up to 16 µM, were mixed with 2 µM protein 
and 1:500 Protein Thermal Shift dye in 20 mM HEPES-NaOH pH 7.5, 150 mM KCl, 5% glycerol, 1 mM 
DTT and 20 ng/µL yeast tRNA (Ambion). For testing the stability of IFIT proteins and complexes, in an 
optical 96-well reaction plate (Applied Biosystems), 2.5 µg protein was mixed with 1:500 Protein Thermal 
Shift dye (Life Technologies) in 20 mM HEPES-NaOH pH 7.5, 150 mM KCl, 2.5 mM MgOAc, 5% 
glycerol and 1 mM DTT, in a final volume of 20 µL. Emission was measured at 623 nm in a ViiA7 Real-
Time PCR system (Applied Biosystems), ramping from 25 to 95 ˚C stepwise at a rate of 1 ˚C per 20S. For 
interpolation of melting temperatures, data were analysed using the Bolzmann equation (y = LL +(UL –
LL)/(1 + exp(Tm – x)/1)) where LL and UL are the minimum and maximum fluorescence intensities, 
respectively, and melting temperature (Tm) was interpolated from the 50% intersect of the curve. 
 
Size-exclusion chromatography multi-angle light scattering 
Ifit proteins (1 mg/mL) were analysed by size exclusion chromatography (SEC) on a Superdex 200 Increase 
10/300 GL column at 4 ˚C at a flow rate of 0.5 mL/min. Ifit complexes were examined by combining Ifit 
proteins at stoichiometric concentrations for 1 hour at 4 ˚C or 30 ˚C, before SEC analysis. 280 nm 
absorbance was normalised such that peak height was equal to 1, for ease of comparison. For SEC-MALS, 
Ifit1b (0.5 or 2 mg/mL in a 150 µL loop) was applied to a Superdex 200 Increase 10/300 GL column at 
room temperature, at a flow rate of 0.4 mL/min. Multi-angle light scattering (MALS) analysis was 
performed by inline measurement of static light scattering (DAWN 8+, Wyatt Technology), differential 
refractive index (Optilan T-rEX, Wyatt Technology) and 280 nm absorbance (Aligent 1260 UV, Aligent 
Technologies). Molecular mass was calculated using the AS-TRA6 software package (Wyatt Technology). 
Access to SEC-MALS apparatus was kindly provided by Dr Janet Deane. 
 
Cell lines 
Human embryonic kidney (HEK293T), murine macrophage-like (RAW264.7) and murine embryonic 
fibroblast (MEF) cell lines all from ATCC were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with 4.5 mg/mL glucose supplemented with 10% foetal calf serum, 2 mM L-glutamine, penicillin 
(100 SI units/mL) and streptomycin (100 µg/mL). Murine 17 clone 1 (17Cl-1) cells, derived from 
spontaneously transformed BALB/c 3T3 fibroblasts (30), kindly shared by Dr Nerea Irigoyen, were 
maintained in DMEM with 1 mg/mL glucose.  
 
Transfection of mammalian cells 
For Ifit induction experiments, cells were stimulated with 2 µg polyI:C (Sigma) transfected using 
Lipofectamine 2000 (Invitrogen). To determine Ifit promoter activity, 17Cl-1 cells were transfected at 70% 
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confluency with 800 ng pGL3-Ifit promoter plasmid and 200 ng pRL-TK, using Lipofectamine 2000. After 
6 hours, cells were stimulated with 1:100 recombinant IFNb (produced as described above). Cells were 
harvested after 24 hours by washing in PBS and lysis in passive lysis buffer (Promega). Promoter activity 
was measured using the Dual-Glo luciferase assay system (Promega) with a Glomax luminometer 
(Promega). Fluc signal was normalised to Rluc signal, and fold changes were calculated between IFN-
treated and mock-treated wells. For puromycylation experiments, 17Cl-1 cells were transfected with 2 µg 
per well pCDNA3.1-FLAG-Ifit plasmids, or empty pCDNA3.1, using Lipofectamine 2000. After 16 hours, 
nascent proteins were labelled using puromycin at 5 µg/mL for 4 hours. Cells were harvested by washing 
in PBS and lysis in passive lysis buffer. Puromycin signal was detected by immunoblotting, as described 
below, and was quantified using ImageJ, normalised to the tubulin signal. For Ifit co-expression 
experiments, 17Cl-1 cells were seeded into 6 well plates containing glass coverslips. At 60% confluency, 
2.5 pmol Ifit coexpression plasmids (described above) were transfected using Lipofectamine 2000. After 
24 hours, coverslips were fixed and stained for immunofluorescence microscopy, as described below, and 
surrounding cells from the same well were harvested for immunoblotting using passive lysis buffer.  
 
Electroporation of mammalian cells 
For infection experiments, transfection using Lipofectamine 2000 inhibited infection, therefore plasmids 
were transfected by electroporation. 1x106 17Cl-1 cells were mixed with 2.5 pmol Ifit coexpression 
plasmids (described above) in 100 µL Opti-MEM (Gibco), in a 2 mm electroporation cuvette. Cells were 
electroporated using a NEPA21 electroporator (Nepagene) at 125V for 7.5 seconds. Cells were seeded 
subconfluently into 24 well plates with glass coverslips, or into T25 flasks, and left to recover for 18 hours 
before infection.  
 
Virus culture 
Recombinant mouse hepatitis virus strain A59 (MHV-A59) was a gift from Dr Nerea Irigoyen, derived 
from a full-length cDNA clone, as described (57, 58). 18 hours after plasmid electroporation, cells were 
infected at a multiplicity of infection (MOI) of 0.1 or 5 PFU/cell in low glucose DMEM containing 50 
µg/mL DEAE-dextran and 0.2% BSA. After 45 minutes at 37 ˚ C, inoculum was removed and replaced with 
fresh media. After 14 hours, cells on coverslips were fixed and stained for immunofluorescence microscopy 
and cells in T25 flasks were trypsinised, fixed and stained in suspension for flow cytometry analysis 
(described below). 
 
Quantitative PCR 
qPCR primers were designed to detect Ifit1b, Ifit1c, Ifit2, Ifit3 and Ifit3b, within the coding sequence of 
the second exon (Table S1). Primers for Ifit1 have been described (59). End-point PCR was performed 
using Taq polymerase (Invitrogen) on 10 ng pTriEx1.1-Ifit template plasmid to verify primer specificity. 
RNA was extracted from cell lysates in passive lysis buffer, using TRI reagent (Sigma) and cDNA was 
generated using Moloney murine leukemia virus reverse transcriptase (Promega) and random hexamer 
primers. qPCR was performed using the qPCR core kit for SYBR green I with low ROX passive reference 
(Eurogentec), with the manufacturer’s recommended parameters: 95 ˚C for 15 seconds then 60 ˚C for 1 
minute, for 50 cycles. Data were normalised against GAPDH and expressed as fold change over mock (2-
ddCq). 
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To verify linear amplification, 10-fold serial dilutions of linearised Ifit plasmid were made from 100 ng 
(1.5 x 1010 copies) to 10 ag (1.5 copies) of DNA per well and qPCR was performed as described above. 
Linear regression was performed on CT values plotted against log10-transformed DNA mass, to ensure PCR 
efficiency was within acceptable parameters (90-110%). To verify target specificity, qPCR products 
amplified from IFN-treated RAW264.7 cells were purified by gel extraction, and Sanger sequenced. 
 
SDS-PAGE and immunoblotting 
Proteins were resolved by 12.5% SDS-PAGE. Where similarly-sized proteins were difficult to resolve, 
proteins were separated on precast 4-12 % NuPAGE Bis-Tris gels (Invitrogen) in MES buffer (Invitrogen) 
(co-precipitation experiments, Figure 6), at 180V for 110 minutes at 4 °C. Gels were stained using 
coomassie brilliant blue R, destained in 25% ethanol and imaged using a LiCor Odyssey imaging system. 
For immunoblotting, separated proteins were transferred to 0.45 µm nitrocellulose membrane. Membranes 
were probed with anti-Ifit1 (sc-134949, Santa Cruz, 1:500), anti-IFIT1 (PA3-848, Pierce, 1:500; cross-
reactive with murine Ifit1 and Ifit1b), anti-IFIT2 (12604-1-AP, Proteintech, 1:800; cross-reactive against 
murine Ifit2 and Ifit3/3b), anti-GAPDH (AM4300, Invitrogen, 1:8000), anti-tubulin (ab6160, Abcam, 
1:1000), anti-His (34660, Qiagen, 1:1000), anti-FLAG M2-peroxidase (A8592, Sigma, 1:1000), anti-GFP 
(G1544, Sigma, 1:4000) and anti-mCherry (ab213511 Abcam, 1:1000). The mouse monoclonal antibody 
against puromycin was a kind gift from Prof Ian Goodfellow. Rat polyclonal antibodies against Ifit1b and 
Ifit1c were raised and purified by Eurogentec. Ifit1b antiserum was raised against 
CFQMKKATSRENRKRA and ESHKSHIHDSLDELRC peptides and affinity purified against 
ESHKSHIHDSLDELRC. Ifit1c antiserum was raised against CKASNMQPRGEDRKRA and 
CEKHIEETLPRISSQP peptides and affinity purified against CEKHIEETLPRISSQP. Membranes were 
then probed with IRdye secondary antibodies (Li-Cor) and imaged on an Odyssey CLx Imaging System 
(Li-Cor). For puromycylation experiments, to visualise total protein, membranes were stained using 
REVERT (Li-Cor), then destained, before blocking. 
 
Immunofluorescence microscopy 
Cells were fixed in 3% paraformaldehyde in PBS, then permeabilised in 0.1% Triton X-100 in PBS with 
50 mM NH4Cl. Cells were blocked in PBS with 0.2% fish gelatine, 0.02% NaN3 and 0.01% Triton X-100. 
Coverslips were stained with anti-FLAG (F1804, Sigma, 1:1000) and anti-dsRNA (10010500, SCIONS 
English and Scientific consulting, 1:1000) with Alexa Fluor secondary antibodies (Life Technologies), 
before mounting using ProLong Gold Antifade Reagent with 4′,6-diamidino-2-phenulindole (DAPI) 
(Invitrogen). Slides were visualised using either the 10x objective (Figure 4B) or the 60x oil immersion 
objective (Figure 8D,E) of an Olympus IX81 wide field microscope, using Image Pro Plus software. 
Merged pseudocoloured images were generated in ImageJ.  
 
Flow cytometry 
Murine 17Cl-1 cells were electroporated with Ifit expression plasmids, as described above, then seeded into 
T25 flasks. After 24 hours, cells (~2.5 x 106) were infected with MHV A59 at an MOI of 0.05 pfu/cell. 
After 16 hours, cells were harvested by trypsinisation, followed by fixation in 1% paraformaldehyde and 
permeabilisation in ice-cold methanol. Cells were blocked with 2% FCS in PBS, before staining with anti-
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dsRNA (10010500, SCIONS English and Scientific consulting, 1:600) and Alexa Fluor secondary 
antibodies (Life Technologies), before analysis on an Attune NxT flow cytometer (Invitrogen). Data were 
analysed using FlowJo (v. 10.6.2). 
 
Graphs and statistics 
Graphs were generated in GraphPad Prism (v. 7.03) or Microsoft Excel (Micrsosoft Office 2013, Version 
15.0.5119.1000). For pairwise comparisons of data means throughout, data were analysed by two-tailed 
Student’s t-test, assuming unequal variance, as indicated in the figure legends. Nonlinear regression was 
carried out using GraphPad Prism, as described above. 
 
Structural modelling 
RNA secondary structural models and free energy calculations were generated with Mfold (60). Protein 
homology models were generated using SWISS-MODEL (61), based on known IFIT structures as indicated 
in the relevant figure legends. Protein structures were visualised using the PyMOL Molecular Graphics 
System (Version 1.5.0.5, Schrödinger, LLC, www.pymol.org). Structures and models for Figure 9 were 
visualised using Illustrate (62). 
 
Phylogenetic analysis 
Mammalian IFIT mRNA sequences were assembled by Daugherty et al. (2016). Protein sequences were 
aligned using MUSCLE (63) and maximum likelihood trees were built and visualised in Seaview (64) using 
PhyML (65), with 100 bootstrap replicates for statistical support. Sequence alignments of IFIT3 proteins in 
different species were visualised using CIAlign (https://pypi.org/project/cialign/) (66).  
 
Data availability 
All data are contained within the manuscript and online Supporting Information. 
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Figure 1. Induction of Ifit gene expression in stimulated murine cells. 
(A) Genome organisation of the murine Ifit locus. Exons are shown as boxes with arrows indicating the 
direction of the reading frame, and introns as solid black lines. Black asterisks represent canonical 
interferon-stimulated response elements (ISRE) while grey stars indicate putative ISRE-like sequences. For 
Ifit1b, two transcription start sites are annotated. (B-C) RT-qPCR analysis of RNA extracted from (B) 
RAW264.7 cells or (C) 17Cl-1 cells stimulated with IFNb or transfected with polyI:C over 48 hours. Graphs 
show the mean and standard error of two biological replicates. (D-E) Immunoblot analysis of (D) 
RAW264.7 or (E) 17Cl-1 cell lysates extracted at the same time as (C/D). GAPDH is included as a loading 
control for each membrane. See also Figure S1-S4.  
 
Figure 2. Translation inhibition by murine Ifit proteins. 
(A) Schematic of the mRNA 5′ cap. (B) Schematic of the Globin-Fluc mRNA, showing the primer binding 
site for reverse transcription (upper panel) and primer extension analysis of capped Globin-Fluc mRNAs at 
different concentrations, to analyse cap methylation efficiency (lower panel). At lower Mg2+ concentrations, 
additional stops are visible corresponding to 2′-O-methylation of the first and second nucleotides, indicated 
with arrowheads. At high Mg2+ concentrations an additional band is seen at the -1 position, consistent with 
terminal transferase activity of the reverse transcriptase. (C) SDS-PAGE (upper panel) and anti-His (lower 
panel) western blot of recombinant Ifit proteins. (D) In vitro translation of differentially capped Globin-
Fluc reporter mRNAs, normalised to the BSA-only control. Graphs show the mean and the standard error 
of at least three experiments. Data were compared to the BSA-only control by pairwise two-tailed t-tests 
and p values < 0.1 are shown. 
 
Figure 3. Ifit1b inhibits translation of unstructured cap1-RNA. 
(A) Schematics of reporter mRNAs used for in vitro translation. (B-D) In vitro translation of differentially 
capped (B) Globin-Fluc, (C) MHV-Fluc or (D) ZIKV-Fluc, in RRL with increasing concentrations of Ifit1b, 
alongside titrations of Ifit1 on cap0 RNA for comparison (dashed lines). Data were normalised to the BSA-
only control and shown as the mean and the standard error of at least two independent experiments. IC50 
values are listed in Table 1.  
 
Figure 4. Overexpression of Ifit1b inhibits MHV infection.  
(A) Schematics of the MHV genome and experimental design. 17Cl-1 cells were electroporated with eGFP, 
eGFP-Ifit1b, mCherry-Ifit1 or empty vector (EV) 24 hours before infection with MHV strain A59 at an 
MOI of 0.01 pfu/cell. 12 or 14 hours after infection, cells were fixed on coverslips for immunofluorescence 
microscopy or fixed in suspension for flow cytometry analysis, as indicated. Cells were stained for double-
stranded RNA (dsRNA) as a marker for viral replication. (B) Immunofluorescence and bright-field 
microscopy of mock or MHV-infected cells. Fluorescently-tagged Ifit proteins are shown in green, dsRNA 
is shown in magenta, and DAPI-stained nuclei are shown in blue. White arrowheads highlight cells which 
are positive for GFP or mCherry-Ifit1 as well as dsRNA, while open arrowheads highlight cells expressing 
eGFP-Ifit1b which are dsRNA-negative. (C) Flow cytometry analysis of mock (dashed lines) or MHV-
infected (solid lines with shading) cells transfected with GFP (grey), GFP-Ifit1b (green) or GFP-Ifit1b-
WM, an RNA-binding mutant (black). The black vertical line indicates the gate for dsRNA-positive cells 
on the x-axis. Quantification from this gate is shown in the lower panel. Data represent the mean and 
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standard deviation from two independent experiments. Data were compared by pairwise, two-tailed t-tests 
assuming unequal variance and p values <0.1 are shown. See also Figure S5-S7. 
 
Figure 5. RNA binding by Ifit1b. 
(A) Secondary structure prediction of the first 25 nt of the b-globin 5′UTR (globin25) RNA, calculated in 
Mfold (Zuker, 2003). (B) Denaturing PAGE analysis of uncapped, cap0 and cap1 globin25 RNA. (C-D) 
Thermal stability analysis of Ifit1 or Ifit1b with increasing concentrations of cap0 (grey) or cap1 (red) 
globin25 RNA. Quantification is shown in the left panels, expressed as the increase in melting temperature 
(Tm) over protein alone (dTm) (mean ± standard error from two-three independent experiments) and 
representative melt curves are shown in the right panels. Tm’s were derived by non-linear regression using 
the Boltzmann equation, y = LL (UL – LL)/(1 + exp(Tm –x)/a) where LL and UL are lower limit and upper 
limit respectively. See also Figure S8. 
 
Figure 6. Mutational analysis of Ifit1b RNA binding. 
(A) Cartoon representation of the cap binding pocket of human IFIT1 (PDB: 5W5H), coloured by 
subdomain (SD). Bound cap0 oligo-A RNA is shown as black and orange sticks. Residues involved in 
human IFIT1 cap coordination and triphosphate binding are shown as sticks and labelled in black. The 
equivalent residues in murine Ifit1b, where divergent, are listed in red. (B) Coomassie-stained SDS-PAGE 
(upper panel) and anti-His western blot (lower panel) of wildtype (WT) and mutant Ifit1b. (C) Thermal 
shift assay of 2 µM WT and mutant Ifit1b with 4 µM cap0 or cap1 RNA, showing the difference in melting 
temperature (dTm) between protein only and protein with RNA. Graph shows the mean and standard 
deviation of three (cap0) or two (cap1) experimental replicates. (D) A model of Ifit1b (cyan) was generated 
in SWISS-MODEL, based on the structure of human IFIT1 (PDB: 5W5H), and is shown superposed with 
human IFIT1 (yellow). (Left panel) Residues in the cap-binding loop, distal to the 2′-O-hydroxyl group of 
the first RNA nucleotide, which impact cap0/cap1 binding specificity are shown as sticks. (Right panel) 
Residues proximal to the first RNA nucleotide are shown. In murine Ifit1b, a number of mutations (relative 
to IFIT1) are present in this region, which may allow accommodation of 2′-O-methylated/cap1-RNA. 
 
Figure 7. Murine Ifit heterocomplex formation. 
(A) Sequence alignment, showing the conserved YxxxL interaction motif (red box), which mediates 
interaction between human IFIT1 and IFIT3 (uppercase labels), and its conservation in murine Ifit proteins 
(lowercase labels). (B-D) Co-precipitation of Ifit1, Ifit1b and truncated Ifit1c (Ifit1cCTD). MBP-tagged bait, 
or MBP alone, was incubated with prey proteins (lane 1) before binding to amylose resin. Unbound proteins 
were washed away (lanes 2-5) and bound proteins remained on the beads (lane 6). Bound proteins were 
eluted in maltose-containing buffer (lane 7). Ifit3 was included as a negative control in each experiment. 
(E-G) Thermal stability analysis of Ifit proteins and complexes. In (F,G), brighter shades of red indicate 
higher concentrations of Ifit1cCTD. See also Figure S9-S12 and Table 2. 
 
Figure 8. Heterocomplexing enhances murine Ifit stability in mouse cells. 
(A) Schematics of Ifit coexpression plasmids. FP, fluorescent protein (mCherry or eGFP); T2A, thosea 
asigna virus 2A Stop-Go sequence. The Ifit1c sequence was either wildtype (WT) or contained mutations 
in the C-terminal domain to disrupt binding to Ifit1 or Ifit1b (Y456E/L460E, YL). (B-E) 17Cl-1 cells were 
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transfected with control or Ifit expression plasmids for 24 hours, then (B,C) harvested for immunoblotting 
or (D,E) stained for immunofluorescence. In (B,C), quantification of FLAG signal, normalised to GAPDH, 
is shown below each lane. Data represent the mean and standard deviation of two biological repeats. For 
consistency and visual clarity in (D,E), micrographs have been pseudocoloured such that fluorescent 
proteins (both mCherry and eGFP) are shown in green and anti-FLAG signal is shown in magenta. 
Micrographs are representative of at least two independent experiments. See also Figure S13. 
 
Figure 9. Ifit1c enhances translation inhibition by Ifit1 and Ifit1b. 
(A) Schematics of reporter mRNAs used for in vitro translation. (B-D) In vitro translation of MHV-Fluc 
reporter mRNAs in RRL with increasing concentrations of (B) Ifit1, (C) Ifit1b or (D) human IFIT1, in the 
presence or absence of 500 nM Ifit1cCTD, either wildtype (WT) or YxxxL mutant (YL). Data were 
normalised to luciferase activity in the absence of IFIT protein, shown as the mean and standard error of at 
least two independent experiments. See Table 3 for calculated IC50 values. 
 
Figure 10. Model for human IFIT and mouse Ifit function. 
During an antiviral response in humans, IFIT1 is highly expressed following IFN stimulation. Human IFIT1 
binds strongly to cap0-RNA (red) but weakly to cap1-RNA (blue), and inhibits their translation. Cap0-RNA 
is associated with viral infection and is recognised as ‘non-self’, while cellular RNA is typically cap1 
modified and is therefore recognised as ‘self’. As such, IFIT1 strongly inhibits the translation of ‘non-self’ 
viral RNA while only weakly inhibiting ‘self’ cellular RNA. In stimulated mouse cells, murine Ifit1 is 
strongly expressed and binds to cap0-RNA, while murine Ifit1b is poorly expressed and binds strongly to 
cap1-RNA. In this way, murine Ifit1 and Ifit1b acting together can strongly inhibit the translation of ‘non-
self’ viral RNA while weakly inhibiting ‘self’ cellular RNA.  
Human IFIT1 stability and activity is regulated by human IFIT3, which interacts via a conserved C-terminal 
interaction motif. Human IFIT3 also interacts with human IFIT2, via the N-terminus, and regulates IFIT2-
mediated apoptosis. As such the human IFIT1:IFIT2:IFIT3 complex is co-regulated and is involved in 
multiple stages of the antiviral response. Murine Ifit1 and Ifit1b are both regulated by murine Ifit1c, which 
also interacts via the C-terminal domain. Ifit1, Ifit1b and Ifit1c do not bind to Ifit3, therefore the functions 
of Ifit heterocomplexes in mice are regulated separately. 
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Table 1.  Translation inhibition by murine Ifit proteins.  
Values are from data presented in Figure 3. IC50 values are the concentrations of Ifit that reduce reporter 
translation by 50% ± standard error. Data were fitted to [Inhibitor] versus normalized response curve (Y = 
100/(1 + (XHillSlope)/(IC50HillSlope) using the least squares method in GraphPad Prism. 
 
Ifit RNA IC50 (nM Ifit in 
RRL) 
Ifit1b cap0-globin-Fluc 675 ± 129 
Ifit1b cap1-globin-Fluc 152 ± 18.1 
Ifit1b cap2-globin-Fluc 826 ± 183 
Ifit1 cap0-globin-Fluc 102 ± 14.5 
Ifit1b cap0-MHV-Fluc 690 ± 233 
Ifit1b cap1-MHV-Fluc 101 ± 17.9 
Ifit1b cap2-MHV-Fluc 238 ± 50.1 
Ifit1 cap0-MHV-Fluc 68 ± 9.5 
Ifit1b cap1-ZIKV-Fluc 1240 ± 300 
Ifit1 cap0-ZIKV-Fluc 550 ± 240 
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Table 2. Melting temperatures of Ifit proteins and complexes. 
Melting temperatures (Tm) were interpolated from data presented in Figure 6. Data were analysed by 
non-linear regression using the Boltzmann equation, y = LL (UL – LL)/(1 + exp(Tm –x)/a) where LL and 
UL are lower limit and upper limit respectively. 
 
Protein or complex Tm (°C) 
Ifit1 41.9 
Ifit1b 38.3 
Ifit1 + Ifit1cCTD 44.4 
Ifit1b + Ifit1cCTD 41.0 
MBP 57.7 
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Table 3. Translation inhibition by Ifit complexes. 
Values are from data presented in Figure 9. IC50 values are the concentrations of Ifit that reduce reporter 
translation by 50% ± standard error. Data were fitted to [Inhibitor] versus normalized response curve (Y = 
100/(1 + (XHillSlope)/(IC50HillSlope) using the least squares method in GraphPad Prism. *Curves were compared 
by extra sum-of-squares F test. 
 
Ifit or complex RNA IC50 (nM Ifit in 
RRL) 
P-value (Ifit only vs complex)* 
Ifit1b cap1-MHV-Fluc 147 ± 27.8 - 
Ifit1b + MBP-Ifit1cCTD WT cap1-MHV-Fluc 32.6 ± 11.2 <0.0001 
Ifit1b + MBP-Ifit1cCTD YL cap1-MHV-Fluc 191 ± 28.4 0.6630 
Ifit1 cap0-MHV-Fluc 67.9 ± 9.0 - 
Ifit1 + MBP-Ifit1cCTD WT cap0-MHV-Fluc 11.4 ± 5.8 <0.0001 
Ifit1 + MBP-Ifit1cCTD YL cap0-MHV-Fluc 68.7 ± 17.4 0.0577 
IFIT1 cap0-MHV-Fluc 49.8 ± 7.3 - 
IFIT1 + MBP-Ifit1cCTD WT cap0-MHV-Fluc 55.0 ± 7.1 0.5044 
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